Reimbursement can kill a good device.
It doesn't have to kill yours.
A device can be FDA-approved, clinically effective, and still fail — no code, no coverage, or payment that doesn't cover its cost. Ascalon Market Access finds those problems while they can still be solved.
Payment
Does the payment actually cover your device — or does the hospital lose money using it?
Coverage
What do Medicare and the major payers say today — and what evidence would change it?
Coding
Does a defensible code describe your procedure — or is there a gap that changes your timeline?
Full reimbursement requires all three. Most companies find out one is missing later than they should.
Twenty years inside Abbott, Boston Scientific, and Zimmer — now working for you.
Ascalon Market Access is an independent consultancy serving medical device companies and their investors, led by Steve St George — a reimbursement leader who managed coding, coverage, and payment strategy for entire device portfolios before bringing that judgment to companies that can't yet hire it in-house.
Client Result
A coding conclusion that held up through acquisition due diligence.
When a market incumbent told customers the codes couldn't be used with a new competing device, Ascalon's word-by-word analysis found nothing in the code language supporting the claim. The client's trial proceeded on schedule — and the analysis held through acquisition review.
Find out where your device stands.
Every engagement starts the same way: a straight answer about your reimbursement landscape — opportunities, barriers, and what to do next. Fixed fee, scoped in a 30-minute conversation.